Reseña o resumen
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy
Table of contents (5 chapters)
Melanoma Immunotherapy
Gregory A. Daniels MD, PhD
Pages
Combinatorial Checkpoint Blockade Immunotherapy and Radiation
Sangwoo Shawn Kim, Andrew Sharabi
Pages
Cellular Therapy
Aaron M. Goodman MD, Tiffany N. Tanaka MD, Dan S. Kaufman MD, PhD
Pages
Pharmacokinetics and Pharmacodynamics of Immunotherapy
Lisa H. Lam PharmD, Swan D. Lin PharmD, Ji Sun PharmD, PhD
Pages
Immune Checkpoint Combinations with Inflammatory Pathway Modulators
N. DeVito, et al.
Pages